Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the company’s Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time).

A live webcast of the investor presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.

Quince Therapeutics Contact:

Stacy Roughan

Quince Therapeutics, Inc.

Vice President, Corporate Communications & Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Advances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer

Expected to Advance Technology Development and Sales Growth

Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma

Provides Cash Runway through Mid-2024 to Fund Key Milestones

TriSalus’ Common Stock Expected to Begin Trading on the Nasdaq under Symbol “TLSI” on August 11, 2023

DENVER & FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus’ common stock and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols “TLSI” and “TLSIW,” respectively, on August 11, 2023.

“Completing our merger with MedTech marks an important milestone in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and CEO of TriSalus. “Over the last several months we have advanced our device business and generated positive clinical data that supports the potential of our immunotherapeutic program. We are moving forward with the financial resources needed to grow our commercial organization and fund our key milestones through mid-2024. We believe that we are poised to create shareholder value as we continue our work to bring hope and improved treatments to the lives of patients. Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting us to create value for them. I also want to thank our employees, interventional radiologists, and clinical investors and particularly our patients for their unwavering support that has been instrumental in helping us to achieve this milestone.”

“We are excited to complete this merger with TriSalus and support the growth of its innovative devices and treatments,” said Chris Dewey, CEO of MedTech. “We believe that TriSalus has significant near and long-term value creation opportunities through its commercialization strategy and the potential to deploy SD-101 into multiple indications across several lines of therapy. We have full confidence that Mary and the experienced TriSalus team will continue working to meet significant unmet medical needs and delivering value to shareholders.”

The Company’s new board of directors consists of Mats Wahlstrom, Mary Szela, Sean Murphy, Kerry Hicks, Dr. Anil Singhal, Dr. Andrew C. von Eschenbach, Kelly Martin, David J. Matlin and Dr. Arjun (“JJ”) Desai.

Szela continued, “We welcome Andy, Kelly, JJ and David to the Board and look forward to benefiting from their experience across the medical technology, pharmaceutical, healthcare and financial industries.

Innovative Device Technology Combined with Immunotherapeutic Platform Creates Significant Upside Potential

  • Fast-Growing Core Device Business: TriSalus’ commercial stage, FDA cleared TriNav® Infusion System includes the proprietary SmartValve technology. SmartValve enables precision delivery of therapeutics to tumors using the Pressure-Enabled Drug Delivery™ (PEDD) approach. The PEDD approach has been shown to modulate pressure and flow, increasing therapeutic delivery to the tumor while decreasing exposure in normal tissue – an important goal for interventional radiologists focused on better outcomes with less toxicity. PEDD brings the potential to improve patient outcomes and also brings additional expansion opportunities through the delivery of a wide variety of therapeutics. TriNav achieved $8.4 million and $12.4 million in net sales in 2021 and 2022, respectively, and is on track to generate approximately $19.2 million in net sales in 2023.
  • Robust Device Pipeline: TriSalus’ technology pipeline includes a range of devices that use technology expected to substantially improve therapeutic delivery. An FDA cleared delivery system for infusing immunotherapy into pancreatic adenocarcinoma patients is currently under study at MD Anderson Cancer Center. The pipeline also includes a full suite of devices that allows interventional radiologists to optimize therapy delivery across the broad range of solid tumor types, vessel sizes, and with greater precision using intra-procedural flow dynamic data. The first new device expected in the expanded toolkit is the TriNav LV device, designed to optimally address larger vessel sizes, which received 510(k) clearance by the FDA in May 2023 and is targeted for commercial launch in the first half of 2024.

    To accelerate TriSalus’ strategy, James “Jim” Alecxih was recently appointed as President, Device Technology Business. Jim will oversee the development and expansion of the Company’s portfolio of innovative infusion technologies.

  • Therapeutic Platform in Clinical Development: TriSalus is developing SD-101, an investigational immunotherapeutic designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors – an environment that can make current immunotherapies ineffective in the liver and pancreas. SD-101 is a class C TLR9 agonist with a dual mechanism of action and a differentiated profile versus other TLR agonists. In solid tumors, the drug alters the tumor microenvironment by reducing immunosuppressive myeloid-derived suppressor cells (MDSC) while simultaneously stimulating multiple immune cell types.

    Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically. Currently SD-101 is being studied in three clinical trials for patients with uveal melanoma with liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma.

    In the studies reported to date, SD-101 in combination with systemic checkpoint inhibition and delivered with PEDD, achieved high concentrations in the liver with minimal systemic exposure and was well tolerated based on a low SD-101 treatment related serious adverse event rate of 5%, and resulted in immune cell activation and natural killer cell expansion. The immune effects in liver metastases and the blood are consistent with broad tumor microenvironment modulation and the ability of SD-101 to deplete MDSCs in the liver. These findings were highlighted during an oral discussion session at ASCO 2023.

    Additional Phase 1 data readouts for the PERIO clinical trial program are planned in the fourth quarter of 2023 and a Phase 2 trial is scheduled to be initiated in the second half of 2023.

  • Well Positioned with Cash Runway: Proceeds raised in connection with the merger with MedTech, including proceeds from the recently closed private placement transaction and amounts remaining in the MedTech trust account, along with cash on hand, provides a cash runway through mid-2024 to fund key milestones.

Advisors 

Cooley LLP is acting as legal counsel to TriSalus. Raymond James is acting as exclusive financial advisor to MedTech and as the sole placement agent on the convertible offering, and Paul Hastings LLP is serving as legal counsel to the placement agent. Foley & Lardner LLP is acting as legal counsel to MedTech.

For Patients 

To learn more about the clinical trial treatment protocol and enrollment, visit http://www.periotrial.com or http://www.clinicaltrials.gov and search NCT04935229, NCT05220722, and NCT05607953.

About TriSalus Life Sciences

TriSalus Life Sciences® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors.

The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that SD-101 delivered via PEDD may have favorable immune effects within the liver and systemically.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn.

Forward-Looking Statements

Certain statements in this communication may be considered forward-looking statements, including but not limited to statements regarding the Company’s revenue expectations for 2023, the Company’s expectations that the proceeds from the business combination and related transactions provide a cash runway through 2024 and the potential to deploy SD-101 into multiple indications across multiple lines of therapy. Forward-looking statements generally relate to future events and can be identified by terminology such as “aim”, “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by MedTech and its management, and TriSalus and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the risk that the Business Combination disrupts current plans and operations of TriSalus; the outcome of any legal proceedings that may be instituted against TriSalus or MedTech related to the Merger Agreement, or the Business Combination; changes in business, market, financial, political and legal conditions; unfavorable changes in the reimbursement environment for TriSalus’ products; TriSalus’ product candidates not achieving success in preclinical or clinical trials or not being able to obtain regulatory approval, either on a timely basis or at all or subject to any conditions that negatively impact TriSalus’ ability to commercialize the applicable product candidates; TriSalus being unable to continue to grow TriNav sales; the size of the addressable markets for TriNav and SD-101, if successfully developed and approved by the applicable regulatory authorities, being less than TriSalus currently estimates; TriSalus’ ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities; TriSalus’ ability to continue to fund preclinical and clinical trials for SD-101; TriSalus’ ability to partner with other companies; future economic and market conditions; the development, effects and enforcement of laws and regulations affecting TriSalus’ business or industry; TriSalus’ ability to manage future growth; TriSalus’ ability to maintain and grow its market share; the effects of competition on TriSalus’ business; the ability to implement business plans, forecasts and other expectations, and identify and realize additional opportunities; the failure to realize the anticipated benefits of the Business Combination or to realize estimated pro forma results and the underlying assumptions; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration on Form S-4 and other documents filed by the Company from time to time with the Securities and Exchange Commission. The foregoing list of factors is not exclusive. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements. The Company does not give any assurance that it will achieve its expectations.

Media:

[email protected]

Investors:

Aaron Palash / Allison Sobel

Joele Frank, Wilkinson Brimmer Katcher

+1 212 355 4449

KEYWORDS: Florida Colorado United States North America

INDUSTRY KEYWORDS: Health Oncology Clinical Trials

MEDIA:

Onto Innovation Reports 2023 Second Quarter Results

Onto Innovation Reports 2023 Second Quarter Results

WILMINGTON, Mass.–(BUSINESS WIRE)–
Onto Innovation Inc. (NYSE: ONTO) (“Onto Innovation,” “Onto,” or the “Company”) today announced financial results for the second fiscal quarter of 2023.

Second Quarter Financial Highlights

  • Expected revenue reduced by three lithography system shipments that were delayed to add a customer-specific enhancement package, resulting in $191 million quarterly revenue.

  • GAAP gross margin and non-GAAP gross margin of 53%.

  • GAAP operating income of $25 million and GAAP net income of $26 million.

  • Non-GAAP operating income of $41 million and non-GAAP net income of $39 million.

  • GAAP diluted earnings per share of $0.53 and non-GAAP diluted earnings per share of $0.79.

Second Quarter Business Highlights

  • Inspection revenue for heterogeneous packaging of advanced logic processors and high bandwidth memory (HBM) for AI applications represented over $20 million in the quarter, with significant revenue growth anticipated over the next several quarters.

  • Revenue from specialty and advanced packaging customers increased more than 20% over the first quarter.

  • Revenue from power customers grew over 35% from the first quarter, which included systems and software from our inspection, films, overlay, and OCD product lines.

  • IMPULSE® V integrated metrology systems were accepted by two customers, serving the memory and image sensor markets, delivering the precision and stability required to keep pace with the latest generation high speed CMP polishers.

Michael Plisinski, chief executive officer of Onto Innovation, commented, “During the quarter we saw several positive affirmations of our strategy. Our leading position among the top five customers for inspection of heterogeneous packaging and HBM to support the increasing AI end market resulted in solid demand in the quarter and positioned Onto for further inspection growth throughout the year. Demand for our solutions in power semiconductors continued to grow, and we now have a backlog of orders for our recently announced Element materials metrology and Atlas® OCD metrology products specifically designed to support the power market.”

He continued, “Although our advanced node customers remain at significantly reduced spending levels, we have several productive engagements with their R&D teams, resulting in new tool of record positions for our films metrology systems and integrated metrology modules, which should contribute to broader growth when production spending resumes.”

Onto Innovation Inc.

Key Quarterly Financial Data

(In thousands, except per share amounts)

US GAAP

 

 

 

July 1, 2023

 

 

April 1, 2023

 

 

July 2, 2022

 

Revenue

 

$

190,662

 

 

$

199,165

 

 

$

256,310

 

Gross profit margin

 

 

53

%

 

 

53

%

 

 

52

%

Operating income

 

$

24,807

 

 

$

29,035

 

 

$

57,451

 

Net income

 

$

25,896

 

 

$

29,068

 

 

$

51,575

 

Net income per diluted share

 

$

0.53

 

 

$

0.59

 

 

$

1.03

 

US NON-GAAP

 

 

 

July 1, 2023

 

 

April 1, 2023

 

 

July 2, 2022

 

Revenue

 

$

190,662

 

 

$

199,165

 

 

$

256,310

 

Gross profit margin

 

 

53

%

 

 

54

%

 

 

52

%

Operating income

 

$

40,565

 

 

$

48,895

 

 

$

73,096

 

Net income

 

$

38,754

 

 

$

45,047

 

 

$

64,001

 

Net income per diluted share

 

$

0.79

 

 

$

0.92

 

 

$

1.28

 

Outlook

For the third fiscal quarter ending September 30, 2023, the Company is providing the following guidance:

  • Revenue is expected to be $205 to $225 million.

  • GAAP diluted earnings per share is expected to be in the range of $0.59 to $0.79.

  • Non-GAAP diluted earnings per share is expected to be in the range of $0.85 to $1.05.

Webcast & Conference Call Details

Onto Innovation will host a conference call at 4:30 p.m. Eastern Time today, August 10, 2023, to discuss its second quarter 2023 financial results and other matters in greater detail. To participate in the call, please dial (888) 394-8218 or International: +1 (646) 828-8193 and reference conference ID 9525867 at least five (5) minutes prior to the scheduled start time. A live webcast will also be available at www.ontoinnovation.com.

To listen to the live webcast, please go to the website at least fifteen (15) minutes early to register, download and install any necessary audio software. There will be a replay of the conference call available for one year on the Company’s website at www.ontoinnovation.com.

Discussion of Non-GAAP Financial Measures

The Company has provided in this release non-GAAP financial measures, including non-GAAP operating income, non-GAAP net income, non-GAAP diluted earnings per share and non-GAAP operating margin, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, litigation expenses and restructuring costs. Non-GAAP operating income, non-GAAP net income, non-GAAP diluted earnings per share and non-GAAP operating margin can also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to the purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Merger or acquisition related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our mergers and acquisitions, such as transaction and integration costs, change in control payments, adjustments to the fair value of assets, etc. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

Restructuring charges: we incur restructuring and impairment charges on individual or groups of employed assets, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the items identified to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) which include, but are not limited to, statements regarding Onto Innovation’s business momentum and future growth; the benefit to customers and capabilities of Onto Innovation’s products and customer service; Onto Innovation’s ability to both deliver products and services consistent with our customers’ demands and expectations and strengthen its market position; Onto Innovation’s expectations regarding the semiconductor market outlook; Onto Innovation’s future quarterly and annual financial outlook; as well as other matters that are not purely historical data. Onto Innovation wishes to take advantage of the “safe harbor” provided for by the Act and cautions that actual results may differ materially from those projected as a result of various factors, including risks and uncertainties, many of which are beyond Onto Innovation’s control. Such factors include, but are not limited to, the Company’s ability to leverage its resources to improve its position in its core markets; its ability to weather difficult economic environments; its ability to open new market opportunities and target high-margin markets; the strength/weakness of the back-end and/or front-end semiconductor market segments; fluctuations in customer capital spending; the Company’s ability to effectively manage its supply chain and adequately source components from suppliers to meet customer demand; the effects of political, economic, legal, and regulatory changes or conflicts on the Company’s global operations; its ability to adequately protect its intellectual property rights and maintain data security; the effects of natural disasters or public health emergencies, such as the current COVID-19 pandemic, on the global economy and on the Company’s customers, suppliers, employees, and business; its ability to effectively maneuver global trade issues and changes in trade and export regulations and license policies; the Company’s ability to maintain relationships with its customers and manage appropriate levels of inventory to meet customer demands; and the Company’s ability to successfully integrate acquired businesses and technologies. Additional information and considerations regarding the risks faced by Onto Innovation are available in Onto Innovation’s Form 10-K report for the year ended December 31, 2022, and other filings with the Securities and Exchange Commission. As the forward-looking statements are based on Onto Innovation’s current expectations, the Company cannot guarantee any related future results, levels of activity, performance, or achievements. Onto Innovation does not assume any obligation to update the forward-looking information contained in this press release, except as required by law.

About Onto Innovation

Onto Innovation is a leader in process control, combining global scale with an expanded portfolio of leading-edge technologies that include: Un-patterned wafer quality; 3D metrology spanning chip features from nanometer scale transistors to large die interconnects; macro defect inspection of wafers and packages; elemental layer composition; overlay metrology; factory analytics; and lithography for advanced semiconductor packaging. Our breadth of offerings across the entire semiconductor value chain combined with our connected thinking approach results in a unique perspective to help solve our customers’ most difficult yield, device performance, quality, and reliability issues. Onto Innovation strives to optimize customers’ critical path of progress by making them smarter, faster and more efficient. With headquarters and manufacturing in the U.S., Onto Innovation supports customers with a worldwide sales and service organization. Additional information can be found at www.ontoinnovation.com.

Source: Onto Innovation Inc.

ONTO-I

(Financial tables follow)

ONTO INNOVATION INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands) – (Unaudited)

 

 

 

July 1, 2023

 

 

December 31, 2022

 

 

 

 

 

 

ASSETS

 

 

 

 

 

Current assets

 

 

 

 

 

Cash, cash equivalents and marketable securities

 

$

609,603

 

 

$

547,784

Accounts receivable, net

 

 

187,852

 

 

 

241,395

Inventories

 

 

352,073

 

 

 

324,282

Prepaid and other assets

 

 

33,517

 

 

 

21,411

Total current assets

 

 

1,183,045

 

 

 

1,134,872

Net property, plant and equipment

 

 

99,883

 

 

 

91,980

Goodwill and intangibles, net

 

 

510,359

 

 

 

538,008

Other assets

 

 

27,574

 

 

 

30,003

Total assets

 

$

1,820,861

 

 

$

1,794,863

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

85,567

 

 

$

103,362

Other current liabilities

 

 

51,370

 

 

 

57,196

Total current liabilities

 

 

136,937

 

 

 

160,558

Other non-current liabilities

 

 

27,210

 

 

 

37,879

Total liabilities

 

 

164,147

 

 

 

198,437

Stockholders’ equity

 

 

1,656,714

 

 

 

1,596,426

Total liabilities and stockholders’ equity

 

$

1,820,861

 

 

$

1,794,863

ONTO INNOVATION INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts) – (Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

July 1, 2023

 

July 2, 2022

 

July 1, 2023

 

July 2, 2022

Revenue

 

$

190,662

 

 

$

256,310

 

 

$

389,827

 

 

$

497,660

 

Cost of revenue

 

 

90,201

 

 

 

124,183

 

 

 

184,391

 

 

 

234,510

 

Gross profit

 

 

100,461

 

 

 

132,127

 

 

 

205,436

 

 

 

263,150

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

27,043

 

 

 

25,637

 

 

 

54,285

 

 

 

51,978

 

Sales and marketing

 

 

16,024

 

 

 

16,913

 

 

 

31,661

 

 

 

32,545

 

General and administrative

 

 

18,762

 

 

 

18,306

 

 

 

37,999

 

 

 

34,793

 

Amortization

 

 

13,825

 

 

 

13,820

 

 

 

27,649

 

 

 

27,639

 

Total operating expenses

 

 

75,654

 

 

 

74,676

 

 

 

151,594

 

 

 

146,955

 

Operating income

 

 

24,807

 

 

 

57,451

 

 

 

53,842

 

 

 

116,195

 

Interest income, net

 

 

4,758

 

 

 

661

 

 

 

8,206

 

 

 

1,038

 

Other expense, net

 

 

(1,710

)

 

 

(859

)

 

 

(1,991

)

 

 

(1,063

)

Income before income taxes

 

 

27,855

 

 

 

57,253

 

 

 

60,057

 

 

 

116,170

 

Provision for income taxes

 

 

1,959

 

 

 

5,678

 

 

 

5,093

 

 

 

11,265

 

Net income

 

$

25,896

 

 

$

51,575

 

 

$

54,964

 

 

$

104,905

 

Earnings per share:

 

 

 

 

 

 

 

 

Basic

 

$

0.53

 

 

$

1.04

 

 

$

1.12

 

 

$

2.12

 

Diluted

 

$

0.53

 

 

$

1.03

 

 

$

1.12

 

 

$

2.10

 

Weighted average shares

outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

48,976

 

 

 

49,617

 

 

 

48,865

 

 

 

49,525

 

Diluted

 

 

49,274

 

 

 

49,907

 

 

 

49,175

 

 

 

49,909

 

ONTO INNOVATION INC.

NON-GAAP FINANCIAL SUMMARY

(In thousands, except percentage and per share amounts) – (Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

 

July 1, 2023

 

July 2, 2022

 

July 1, 2023

 

July 2, 2022

 

Revenue

$

190,662

 

$

256,310

 

$

389,827

 

$

497,660

 

Gross profit

$

100,501

 

$

132,121

 

$

207,795

 

$

263,139

 

Gross margin as percentage of

revenue

 

53

%

 

52

%

 

53

%

 

53

%

Operating expenses

$

59,936

 

$

59,026

 

$

118,335

 

$

115,780

 

Operating income

$

40,565

 

$

73,096

 

$

89,460

 

$

147,360

 

Operating margin as a

percentage of revenue

 

21

%

 

29

%

 

23

%

 

30

%

Net income

$

38,754

 

$

64,001

 

$

83,801

 

$

129,629

 

Net income per diluted share

$

0.79

 

$

1.28

 

$

1.70

 

$

2.60

 

RECONCILIATION OF GAAP GROSS PROFIT,

OPERATING EXPENSES AND OPERATING INCOME TO NON-GAAP

GROSS PROFIT, OPERATING EXPENSES AND OPERATING INCOME

(In thousands, except percentages) – (Unaudited)

 

 

Three Months Ended

 

Six Months Ended

 

 

July 1, 2023

 

July 2, 2022

 

July 1, 2023

 

July 2, 2022

 

U.S. GAAP gross profit

$

100,461

 

$

132,127

 

$

205,436

 

$

263,150

 

Pre-tax non-GAAP items:

 

 

 

 

 

 

 

 

Merger and acquisition related expenses

 

40

 

 

(6

)

 

80

 

 

(11

)

Restructuring expenses

 

 

 

 

 

2,279

 

 

 

Non-GAAP gross profit

$

100,501

 

$

132,121

 

$

207,795

 

$

263,139

 

U.S. GAAP gross margin as a

percentage of
revenue

 

53

%

 

52

%

 

53

%

 

53

%

Non-GAAP gross margin as a

percentage of revenue

 

53

%

 

52

%

 

53

%

 

53

%

U.S. GAAP operating expenses

$

75,654

 

$

74,676

 

$

151,594

 

$

146,955

 

Pre-tax non-GAAP items:

 

 

 

 

 

 

 

 

Merger and acquisition related expenses

 

393

 

 

662

 

 

1,401

 

 

1,319

 

Restructuring expenses

 

1,192

 

 

 

 

3,226

 

 

 

Litigation expenses

 

308

 

 

1,169

 

 

983

 

 

2,218

 

Amortization of intangibles

 

13,825

 

 

13,820

 

 

27,649

 

 

27,639

 

Non-GAAP operating expenses

 

59,936

 

 

59,025

 

 

118,335

 

 

115,779

 

Non-GAAP operating income

$

40,565

 

$

73,096

 

$

89,460

 

$

147,360

 

GAAP operating margin as a

percentage of revenue

 

13

%

 

22

%

 

14

%

 

23

%

Non-GAAP operating margin

as a percentage of revenue

 

21

%

 

29

%

 

23

%

 

30

%

ONTO INNOVATION INC.

RECONCILIATION OF GAAP NET INCOME TO

NON-GAAP NET INCOME

(In thousands, except share and per share data) – (Unaudited)

 

 

Three Months Ended

Six Months Ended

 

July 1, 2023

July 2, 2022

July 1, 2023

July 2, 2022

U.S. GAAP net income

$

25,896

 

$

51,575

 

$

54,964

 

$

104,905

 

Pre-tax non-GAAP items:

 

 

 

 

Merger and acquisition related expenses

 

434

 

 

656

 

 

1,482

 

 

1,308

 

Restructuring expenses

 

1,192

 

 

 

 

5,505

 

 

 

Litigation expenses

 

308

 

 

1,169

 

 

983

 

 

2,218

 

Amortization of intangibles

 

13,825

 

 

13,820

 

 

27,649

 

 

27,639

 

Net tax provision adjustments

 

(2,901

)

 

(3,219

)

 

(6,782

)

 

(6,441

)

Non-GAAP net income

$

38,754

 

$

64,001

 

$

83,801

 

$

129,629

 

Non-GAAP net income per

diluted share

$

0.79

 

$

1.28

 

$

1.70

 

$

2.60

 

ONTO INNOVATION INC

SUPPLEMENTAL INFORMATION – RECONCILIATION OF THIRD QUARTER 2023

GAAP TO NON-GAAP GUIDANCE

 

Low

High

Estimated GAAP net income per diluted share

$

0.59

 

$

0.79

 

Estimated non-GAAP items:

 

 

 

 

Amortization of intangibles

 

0.28

 

 

0.28

 

Merger and acquisition related expenses

 

0.01

 

 

0.01

 

Litigation expenses

 

0.02

 

 

0.02

 

Net tax provision adjustments

 

(0.05

)

 

(0.05

)

Estimated non-GAAP net income per diluted share

$

0.85

 

$

1.05

 

 

Michael Sheaffer

+1.978.253.6273

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Technology Hardware Semiconductor Other Technology

MEDIA:

Logo
Logo

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today

EMERYVILLE, Calif.–(BUSINESS WIRE)–OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.

“Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs. The addition of four new partners during the quarter, including Merck & Co. and Neurocrine Biosciences, highlights the relevance and robustness of our technology platform. Existing partners made progress with two new programs entering the clinic and the total number of active programs increased to 305,” said Matt Foehr, Chief Executive Officer of OmniAb, Inc.

“Our ion channel business continues to identify and explore high-value targets and one of the GSK programs achieved a key milestone in its discovery process. We look forward to providing updates related to our current partners as well as to securing additional partnerships,” he added.

Second Quarter 2023 Financial Results

Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022. Milestone revenue was higher due to progress with the batoclimab program. Service revenue was lower primarily related to the completion of work on certain ion channel programs and a one-time adjustment related to the extension of one of our programs with GSK, partially offset by the recognition of a portion of a research progression milestone achieved in the quarter.

Research and development expense was $14.1 million for the second quarter of 2023, compared with $11.5 million for the same period in 2022, with the increase primarily due to higher personnel and facility costs. General and administrative expense was $8.7 million for the second quarter of 2023, compared with $5.0 million for the same period in 2022, with the increase primarily due to higher personnel costs and expenses related to being an independent publicly traded company.

Net loss for the second quarter of 2023 was $14.7 million, or $0.15 per share, compared with a net loss of $10.3 million, or $0.12 per share, for the same period in 2022.

Year-to-Date Financial Results

Revenue for the six months ended June 30, 2023 was $23.9 million, compared with $16.8 million for the same period in 2022. Milestone revenue was higher, primarily due to the recognition of a $10.0 million milestone payment related to the first commercial sale of TECVAYLI® (teclistamab) in the European Union and progress with the batoclimab program. Service revenue was lower primarily related to the completion of work on certain ion channel programs and a one-time adjustment related to the extension of one of our programs with GSK, partially offset by the recognition of a portion of a research progression milestone achieved in the quarter.

Research and development expense was $27.9 million for the six months ended June 30, 2023, compared with $22.3 million for the same period in 2022, with the increase primarily due to higher personnel and facility costs. General and administrative expense was $16.9 million for the six months ended June 30, 2023, compared with $9.1 million for the same period in 2022, with the increase primarily due to higher personnel costs and expenses related to being an independent publicly traded company.

Net loss for the six months ended June 30, 2023 was $20.8 million, or $0.21 per share, compared with a net loss of $16.6 million, or $0.20 per share, for the same period in 2022.

As of June 30, 2023, OmniAb had cash, cash equivalents and short-term investments of $103.1 million. The Company continues to expect its cash, cash equivalents and short-term investments balance at year-end 2023 to be slightly higher than year-end 2022. Current cash, cash equivalents and short-term investments, along with the cash OmniAb generates from operations, are expected to be sufficient to fund operations for the foreseeable future.

On November 1, 2022, OmniAb completed a spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), resulting in OmniAb becoming an independent publicly traded company. Financial results prior to November 1, 2022, are presented on a carve-out basis derived from Ligand’s historical accounting records, as if OmniAb were an independent company.

Second Quarter 2023 and Recent Business Highlights

During the second quarter of 2023, OmniAb entered into four new license agreements including with Merck & Co., Inc., Neurocrine Biosciences Inc., Stanford University and Seattle Children’s Hospital. These additions bring the total active partner count to 74.

Programs by OmniAb’s partners continued to progress during the quarter, including two entering the clinic. Immunovant’s IMVT-1402, a next-generation FcRn antagonist, and Gloria’s GLS-012 (anti-LAG-3), initiated Phase 1 clinical trials in China. In addition, the Biologics License Application for batoclimab was accepted by the National Medical Products Administration of China (NMPA). Batoclimab continues to progress in clinical trials in other geographies. As of June 30, 2023, the Company’s partners had a total of 305 active programs. There are 29 active programs that have advanced into the clinical stage or later, including three approved drugs, one under regulatory review and 25 in various stages of clinical development.

Second quarter 2023 and recent partner highlights include the following:

Batoclimab

  • OmniAb earned milestone revenue related to the advancement of batoclimab into pivotal studies in two additional indications: thyroid eye disease and chronic inflammatory demyelinating polyneuropathy. These indications are in addition to the ongoing Phase 3 study in generalized myasthenia gravis (gMG).

  • Harbour BioMed announced the NMPA accepted the Biologics License Application of batoclimab for the treatment of gMG.

  • HanAll Biopharma announced it is progressing toward initiation of a Phase 3 clinical study in Japan later this year with batoclimab in gMG.

IMVT-1402

  • Immunovant announced it received Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) for IMVT-1402, a subcutaneously-administered FcRn inhibitor, and initiated a Phase 1 clinical trial in healthy volunteers. This trial will evaluate the safety, tolerability and pharmacodynamics of IMVT-1402. Initial data are expected later this year.

GLS-012

  • Gloria Pharmaceuticals initiated a Phase 1/2 study in China to investigate the safety, tolerability and preliminary efficacy of GLS-012 (anti-LAG-3) monotherapy and in combination with GLS-010 in subjects with advanced solid tumors after progression on standard treatment.

CSX-1004

  • Cessation Therapeutics announced that the FDA has authorized the company to initiate a clinical trial in the U.S. for CSX-1004, a monoclonal antibody designed specifically to prevent fentanyl overdose. Cessation announced plans to begin trials with the first cohort of subjects in August of 2023.

APVO436

  • Aptevo Therapeutics announced that its bispecific acute myeloid leukemia (AML) drug candidate APVO436, in combination with emerging standard-of-care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose-escalation trial. Aptevo intends to conduct two Phase 2 clinical trials to include relapsed/refractory AML patients beginning in the second half of 2023 and frontline patients beginning in the first half of 2024.

GSK Program-1 (Ion Channels and Transporters)

  • OmniAb achieved a research progression milestone for small molecule inhibitors of a genetically-validated target relevant to neurological diseases in collaboration with GSK. Upon this achievement, OmniAb was entitled to a progression milestone payment of $2.0 million.

In May 2023, OmniAb highlighted some of its new technology at the 19th Annual PEGS Boston Conference and Expo, including a presentation on its OmniDeep platform. OmniDeep is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. OmniDeep facilitates rapid identification of candidates with the right affinity, specificity and developability profiles to make drug development more effective and efficient.

Conference Call and Webcast

OmniAb management will host a conference call with slides today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. To participate via telephone, please dial (888) 396-8049 using the conference ID 10758721. Slides, as well as the live and replay webcast of the call, are available at https://investors.omniab.com/investors/events-and-presentations/default.aspx.

About OmniAb®

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.

The OmniAb suite of technologies span from BI-powered repertoire generation to cutting-edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

Forward-Looking Statements

OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the growth prospects of our business and the discovery needs of the pharmaceutical industry; the expected performance of, our technologies and the opportunities they may create; the ability to add new partners and programs; scientific presentations and clinical and regulatory events of our partners and the timing thereof; expected cash runway; and the future balance of cash, cash equivalents and short-term investments. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions, including adverse developments with respect to financial institutions and associated liquidity risk, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in the our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Partner Information

The information in this press release regarding partnered products and programs comes from information publicly released by our partners.

[Tables Follow]

OMNIAB, INC.

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS

(in thousands, except share and per share data)

 

June 30, 2023

(Unaudited)

 

December 31, 2022

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

20,988

 

 

$

33,390

Short-term investments

 

82,161

 

 

 

54,875

Accounts receivable, net

 

8,611

 

 

 

30,290

Prepaid expenses and other current assets

 

4,180

 

 

 

6,395

Total current assets

 

115,940

 

 

 

124,950

Intangible assets, net

 

161,921

 

 

 

167,242

Goodwill

 

83,979

 

 

 

83,979

Property and equipment, net

 

19,226

 

 

 

19,979

Operating lease right-of-use assets

 

20,827

 

 

 

21,483

Other long-term assets

 

3,346

 

 

 

3,579

Total assets

$

405,239

 

 

$

421,212

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

2,359

 

 

$

2,971

Accrued expenses and other current liabilities

 

4,929

 

 

 

5,557

Income tax payable

 

3,455

 

 

 

3,485

Current contingent liabilities

 

2,810

 

 

 

4,022

Current deferred revenue

 

7,271

 

 

 

8,207

Current operating lease liabilities

 

3,417

 

 

 

1,780

Total current liabilities

 

24,241

 

 

 

26,022

Long-term contingent liabilities

 

3,384

 

 

 

4,089

Deferred income taxes, net

 

17,189

 

 

 

21,341

Long-term operating lease liabilities

 

23,100

 

 

 

24,016

Long-term deferred revenue

 

3,479

 

 

 

4,325

Other long-term liabilities

 

40

 

 

 

46

Total liabilities

 

71,433

 

 

 

79,839

Stockholders’ equity:

 

 

 

Preferred stock, $0.0001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022

 

 

 

 

Common stock, $0.0001 par value; 1,000,000,000 shares authorized at June 30, 2023 and December 31, 2022; 115,584,520 and 115,218,229 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

12

 

 

 

12

Additional paid-in capital

 

343,419

 

 

 

330,100

Accumulated other comprehensive income

 

(49

)

 

 

9

(Accumulated deficit) Retained earnings

 

(9,576

)

 

 

11,252

Total stockholders’ equity

 

333,806

 

 

 

341,373

Total liabilities and stockholders’ equity

$

405,239

 

 

$

421,212

OMNIAB, INC.

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Revenues:

 

 

 

 

 

 

 

License and milestone revenue

$

4,330

 

 

$

2,325

 

 

$

16,976

 

 

$

6,426

 

Service revenue

 

2,451

 

 

 

4,735

 

 

 

6,409

 

 

 

9,994

 

Royalty revenue

 

165

 

 

 

139

 

 

 

480

 

 

 

402

 

Total revenues

 

6,946

 

 

 

7,199

 

 

 

23,865

 

 

 

16,822

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

14,133

 

 

 

11,484

 

 

 

27,892

 

 

 

22,256

 

General and administrative

 

8,738

 

 

 

5,003

 

 

 

16,933

 

 

 

9,115

 

Amortization of intangibles

 

3,380

 

 

 

3,113

 

 

 

6,749

 

 

 

6,518

 

Other operating expense (income), net

 

140

 

 

 

165

 

 

 

189

 

 

 

(278

)

Total operating expenses

 

26,391

 

 

 

19,765

 

 

 

51,763

 

 

 

37,611

 

Loss from operations

 

(19,445

)

 

 

(12,566

)

 

 

(27,898

)

 

 

(20,789

)

Other income:

 

 

 

 

 

 

 

Interest income

 

1,285

 

 

 

 

 

 

2,609

 

 

 

 

Other expense

 

(4

)

 

 

 

 

 

(4

)

 

 

 

Total other income, net

 

1,281

 

 

 

 

 

 

2,605

 

 

 

 

Loss before income taxes

 

(18,164

)

 

 

(12,566

)

 

 

(25,293

)

 

 

(20,789

)

Income tax benefit

 

3,436

 

 

 

2,290

 

 

 

4,465

 

 

 

4,231

 

Net loss

$

(14,728

)

 

$

(10,276

)

 

$

(20,828

)

 

$

(16,558

)

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

$

(0.15

)

 

$

(0.12

)

 

$

(0.21

)

 

$

(0.20

)

Weighted-average shares outstanding, basic and diluted

 

99,493

 

 

 

82,612

 

 

 

99,326

 

 

 

82,612

 

 

OmniAb, Inc.

Neha Singh, Ph.D.

[email protected]

Twitter @OmniAbTech

(510) 768-7760

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health General Health Research Pharmaceutical Science Biotechnology

MEDIA:

NUBURU, Inc. Announces Second Quarter 2023 Results

NUBURU, Inc. Announces Second Quarter 2023 Results

Second quarter revenue of $1.1 million, representing a 2,000+% year-over-year increase

Completed a private placement with existing and new investors

CENTENNIAL, Colo.–(BUSINESS WIRE)–NUBURU, Inc. (“NUBURU” or the “Company”) (NYSE American: BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced its financial results for the second quarter ended June 30, 2023.

Financial and Operational Highlights

  • Total sales of $1.1 million, an increase of 2,125% compared to the second quarter of 2022.

  • Introduced the BL-1000 series, a next generation 1 kilowatt blue laser technology, to target large, fast-growing EV battery production, metal 3D printing and consumer electronics markets.
  • Continued to deliver units to Essentium as part of a multi-year partnership focused on metal 3D printing for the aerospace, automotive, and defense markets.

  • Delivered the first blue area printing head as part of the previously announced AFWERX contract to GE Additive for testing.

“We are pleased to report another period of strong financial performance, with total sales of $1.1 million in the second quarter of 2023,” said Dr. Mark Zediker, CEO and Co-Founder of NUBURU. “Our top line improved over 2,000% on a year-over-year basis, supported by the strong market adoption of our transformational blue laser technology and continued execution of product deliveries to our commercial customers, Essentium and GE Additive. Our heads-down approach in delivering the highest quality and energy efficient manufacturing solutions remains our top priority and is underpinned by the progress we’ve made in introducing additional product lines within our core technology portfolio.

“With the recent product launch of our new NUBURU BL™ Series Laser, our market positioning for long-term growth continues to develop,” added Zediker. “In tandem with the accelerating market demand we recognize for sustainable welding and 3D printing technologies, we’ve also witnessed an increased interest in our products by blue chip customers such as NASA. As announced earlier this month, we’ve signed a contract with NASA, showcasing the breadth of possible applications for our IP-protected technology.

“As we look forward to the remainder of the year, we remain cognizant of the supply chain conditions that present bottlenecks in the procurement process for scanner and lens related components. However, with alternative sourcing initiatives in place, we believe such material constraints will abate toward the end of the second half of this year. As part of our top-down approach to boost gross margins and revenue expansion, our team consistently assesses opportunities for implementing operational efficiencies and cost-saving measures – all of which reinforces our confidence in achieving Full Year sales in excess of $3 million.”

Financial Results for the Second Quarter Ended June 30, 2023 as Compared to the Second Quarter 2022

Total revenues were $1.1 million compared to $0.04 million, or a 2,125% year-over-year increase, primarily due to an increase in the number of laser system revenues and the product and customer mix of laser system revenues during the same period.

Total gross profit (loss) was $(1.4) million, compared to $(1.2) million, primarily attributable to a one-time write off of approximately $0.6 million related to excess and obsolete AO product line inventory.

Gross margin was (136)%, compared to (2,574)%, driven by increasing revenue and partially offset by the one-time impact of the AO product line inventory write off.

Total operating expenses were $5.0 million, compared to $2.7 million. The increase is primarily attributable to one-time professional fees associated with legal, compliance and accounting matters following the business combination and the transitioning to being a public company. Further contributors to the increase were regular general and administrative costs associated with the Company’s status as a public company and increased costs for research and development of tooling and supplies related to the development of the BL product line.

Net loss was $6.1 million, or $0.18 per share, compared to $3.9 million, or $0.71 per share, as a result of the above-described increase in total operating expenses.

EBITDA was $(6.0) million, compared to $(3.8) million.

Capital expenditures were $0.5 million, compared to $0.1 million. The increase is primarily driven by the increase in production capabilities to support additional product lines.

Free cash flow was $(5.1) million, compared to $(2.9) million, primarily attributable to the increase in total operating expenses.

Cash and cash equivalents were $6.6 million as of June 30, 2023.

Financial Outlook

The Company reiterated its 2023 outlook of total revenue in excess of $3 million, EBITDA in the range of negative $21.0 million and negative $23.0 million, and free cash flow to be in the range of negative $24 million and negative $26 million. The Company believes that it has access to sufficient sources of capital to fund this business plan.

Conference Call and Webcast

NUBURU will hold a conference call to discuss financial results on Thursday, August 10, 2023 at 2:30 p.m. MT / 4:30 p.m. ET. The dial-in number is (888) 886-7786 for domestic callers, conference ID 67606887. A live webcast of the conference call will be available on the investor relations page of NUBURU’s corporate website at http://ir.nuburu.net/events-and-presentations/default.aspx.

After the live webcast, a replay will remain available online on the investor relations page of NUBURU’s website, under “Events & Presentations” for 90 days following the call.

About NUBURU®

Founded in 2015, NUBURU, Inc. (NYSEAM: BURU) is a developer and manufacturer of industrial blue lasers that leverage fundamental physics and their high-brightness, high-power design to produce faster, higher quality welds and parts than current lasers can provide in laser welding and additive manufacturing of copper, gold, aluminum and other industrially important metals. NUBURU’s industrial blue lasers produce minimal to defect-free welds that are up to eight times faster than the traditional approaches – all with the flexibility inherent to laser processing. For more information, please visit www.nuburu.net.

Non-GAAP Measures

This release includes GAAP and non-GAAP income and per-share earnings data and other GAAP and non-GAAP financial information. We believe that non-GAAP financial information, when taken collectively and in context, may be helpful to investors in assessing our operating performance and trends and in comparing our financial measures with those of comparable companies that may present similar non-GAAP financial measures. The non-GAAP measures included in this release are not in accordance with, or an alternative for, similar measures calculated under generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. NUBURU believes EBITDA and Free Cash Flow are useful in evaluating our operational performance. We use these non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We also use these non-GAAP measures to assess performance against business objectives, make business decisions, develop budgets, forecast future periods, assess trends, and evaluate financial impacts of various scenarios. Additionally, we believe that these non-GAAP measures, in combination with its financial results calculated in accordance with GAAP, provide investors with additional perspective. To gain a complete picture of all effects on our financial results from any and all events, management does (and investors should) rely upon the GAAP measures as well, as the items excluded from non-GAAP measures may contribute to not accurately reflecting the underlying performance of the company’s continuing operations for the period in which they are incurred. Furthermore, the use of non-GAAP measures has limitations in that such measures do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP, and these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including certain financial forecasts and projections and relationships with customers and third parties. All statements other than statements of historical fact contained in this press release may be forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “seek,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by NUBURU and its management, are inherently uncertain and many factors may cause the company’s actual results to differ materially from current expectations which include, but are not limited to: (1) manufacturing and delivery of products could be delayed by supply constraints, manufacturing capacity constraints, shortages of skilled labor, unexpected defects or bugs in the manufacturing process or the product, and other risks typical for highly sophisticated products, particularly at an early stage of manufacturing ramp; (2) delays or other difficulties in product development,(3) the inability to access sufficient capital, whether from Lincoln Park Capital or other sources, to operate as anticipated; (4) customers may order fewer products than anticipated, (5) the Company may receive less revenue than anticipated from multi-year, multi-company government contracts, (6) failure to retain and recruit key personnel, including key executives and skilled engineers, could compromise the Company’s ability to sell products or to develop new products in timely fashion ; (6) the Company could be adversely affected by other economic, business and/or competitive factors, including volatility in the financial system and markets caused by geopolitical and economic factors; (7); and (8) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in NUBURU’s most recent periodic report on Form 10-K or Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. NUBURU does not give any assurance that it will achieve its expected results. NUBURU assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by applicable law.

NUBURU, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

Three Months Ended

June 30,

Six Months Ended

June 30,

 

2023

 

2022

 

2023

 

2022

Revenues

$

1,054,062

 

$

47,375

 

$

1,524,051

 

 

$

137,375

 

Cost of revenues

 

 

2,485,264

 

 

 

1,266,892

 

 

 

3,697,701

 

 

 

1,821,944

 

Gross margin

 

(1,431,202

)

 

(1,219,517

)

 

(2,173,650

)

 

 

(1,684,569

)

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

1,619,411

 

 

987,032

 

 

2,951,716

 

 

 

1,618,533

 

Selling and marketing

 

 

366,406

 

 

 

159,179

 

 

 

542,662

 

 

 

507,959

 

General and administrative

 

3,024,013

 

 

1,531,330

 

 

6,074,272

 

 

 

2,374,373

 

Total operating expenses

 

5,009,830

 

 

2,677,541

 

 

9,568,650

 

 

 

4,500,865

 

Loss from operations

 

 

(6,441,032

)

 

 

(3,897,058

)

 

 

(11,742,300

)

 

 

(6,185,434

)

Interest income

 

 

12,489

 

 

 

3,721

 

 

 

44,916

 

 

 

4,303

 

Interest expense

 

 

(12,384

)

 

 

(2,214

)

 

 

(12,384

)

 

 

(2,214

)

Other income, net

 

334,215

 

 

 

 

835,539

 

 

 

 

Loss before provision for income taxes

 

$

(6,106,712

)

 

$

(3,895,551

)

 

$

(10,874,229

)

 

$

(6,183,345

)

Provision for income taxes

 

 

 

 

 

 

 

 

 

 

 

 

Net loss and comprehensive loss

$

(6,106,712

)

$

(3,895,551

)

$

(10,874,229

)

 

$

(6,183,345

)

Net loss per share, basic and diluted

$

(0.18

)

$

(0.71

)

$

(0.36

)

 

$

(1.15

)

Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted

 

34,776,044

 

 

5,525,140

 

 

30,171,187

 

 

 

5,368,105

  

 

NUBURU, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

 

 

 

June 30,

2023

 

December 31,

2022

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

$

6,624,736

 

 

$

2,880,254

 

Accounts receivable, net

 

 

646,935

 

 

 

327,200

 

Inventories, net of allowance of $962,388 and $292,990, respectively

 

 

567,927

 

 

 

972,695

 

Deferred financing costs

 

 

 

 

 

4,258,515

 

Prepaid expenses and other current assets

 

 

751,977

 

 

 

46,737

 

Total current assets

 

 

8,591,575

 

 

 

8,485,401

 

Property and equipment, net

 

 

4,337,662

 

 

 

3,771,849

 

Construction in progress

 

 

120,051

 

 

 

188,912

 

Right-of-use assets

 

 

488,513

 

 

 

641,651

 

Other assets

 

 

34,359

 

 

 

34,359

 

TOTAL ASSETS

 

$

13,572,160

 

 

$

13,122,172

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable

 

$

4,061,495

 

 

$

4,456,587

 

Accrued expenses

 

 

1,584,640

 

 

 

2,312,118

 

Current portion of operating lease liability

 

 

358,266

 

 

 

343,049

 

Contract liabilities

 

 

180,075

 

 

 

178,750

 

Current portion of convertible notes payable

 

 

 

 

 

7,300,000

 

Total current liabilities

 

 

6,184,476

 

 

 

14,590,504

 

Operating lease liability

 

 

189,518

 

 

 

373,907

 

Convertible notes payable

 

 

6,713,241

 

 

 

 

Warrant liabilities

 

 

501,324

 

 

 

 

TOTAL LIABILITIES

 

 

13,588,559

 

 

 

14,964,411

 

Commitments and Contingencies (Note 6)

 

 

 

 

 

 

Stockholders’ Equity (Deficit)

 

 

 

 

 

 

Convertible preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,038,905 and 23,237,703 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

304

 

 

 

4,040

 

Common stock, $0.0001 par value; 250,000,000 shares authorized; 35,288,220 and 5,556,857 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

3,529

 

 

 

1,077

 

Additional paid-in capital

 

 

72,046,305

 

 

 

59,344,952

 

Accumulated deficit

 

 

(72,066,537

)

 

 

(61,192,308

)

Total Stockholders’ Equity (Deficit)

 

 

(16,399

)

 

 

(1,842,239

)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

$

13,572,160

 

 

$

13,122,172

 

 

Key Operating and Financial Metrics (Non-GAAP Results)

The following tables present our key performance indicators for the three months ended June 30, 2023.

Three Months Ended

June 30,

 

 

 

2023

 

2022

 

$ Change

Revenues

$

1,054,062

 

$

47,375

 

$

1,006,687

 

Total gross margin

 

 

(1,431,202

)

 

 

(1,219,517

)

 

 

(211,685

)

EBITDA(1)

 

(6,007,916

)

 

(3,751,569

)

 

(2,256,347

)

Capital expenditures

 

 

(481,071

)

 

 

(83,091

)

 

 

(397,980

)

Free cash flow(1)

 

(5,130,306

)

 

(2,910,144

)

 

(2,220,162

)

The following tables present our key performance indicators for the six months ended June 30, 2023.

Six Months Ended

June 30,

 

 

 

2023

 

2022

 

$ Change

Revenues

$

1,524,051

 

$

137,375

 

$

1,386,676

 

Total gross margin

 

 

(2,173,650

)

 

 

(1,684,569

)

 

 

(489,081

)

EBITDA(1)

 

(10,681,745

)

 

(5,894,648

)

 

(4,787,097

)

Capital expenditures

 

 

(825,872

)

 

 

(185,472

)

 

 

(640,400

)

Free cash flow(1)

 

(9,525,680

)

 

(4,915,742

)

 

(4,609,938

)

(1) EBITDA and Free cash flow are non-GAAP financial measures. See “Non-GAAP Information” below for our definitions of, and additional information about, EBITDA and Free cash flow and for a reconciliation to the most directly comparable U.S. GAAP financial measures.

Non-GAAP Information

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operational performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively and in context, may be helpful to investors in assessing our operating performance and trends and in comparing our financial measures with those of comparable companies that may present similar non-GAAP financial measures.

EBITDA and Free Cash Flow

We define “EBITDA” as income (loss), plus (minus) depreciation and amortization expenses, plus (minus) interest, plus (minus) taxes and “Free cash flow” as net cash from (used in) operating activities less capital expenditures. EBITDA and Free cash flow are intended as supplemental measures of our performance that are neither required by, nor presented in accordance with, GAAP and these measures should not be considered a substitute for net income (loss), and net cash used in operating activities reported in accordance with GAAP. Our computation of EBITDA and Free cash flow may not be comparable to other similarly titled measures computed by other companies, because all companies may not calculate EBITDA or Free cash flow in the same fashion.

Limitations of Non-GAAP Measures

There are a number of limitations related to EBITDA, including the following:

  • EBITDA excludes certain recurring, non-cash charges, such as depreciation of property and equipment and/or amortization of intangible assets. While these are non-cash charges, we may need to replace the assets being depreciated and amortized in the future and EBITDA does not reflect cash requirements for these replacements or new capital expenditure requirements.

  • EBITDA does not reflect interest expense, net, which may constitute a significant recurring expense in the future.

  • Free cash flow does not reflect the impact of equity or debt raises or repayment of debt or dividends paid.

Because of these and other limitations, EBITDA and Free cash flow should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using EBITDA and Free cash flow on a supplemental basis. You should review the reconciliation of our net loss to EBITDA and net loss to Free cash flow below and not rely on any single financial measure to evaluate our business.

Our presentation of EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items and our presentation of Free cash flow does not necessarily indicate whether cash flows will be sufficient to fund our cash needs.

Reconciliation

The following table reconciles our net loss (the most directly comparable GAAP measure to EBITDA) to EBITDA for the period presented:

Three Months Ended

June 30,

Six Months Ended

June 30,

 

2023

 

2022

 

2023

 

2022

Net loss

$

(6,106,712

)

$

(3,895,551

)

$

(10,874,229

)

$

(6,183,345

)

Interest (income) expense, net

 

 

(105

)

 

 

(1,507

)

 

 

(32,532

)

 

 

(2,089

)

Income tax expense

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

98,901

 

 

 

145,489

 

 

 

225,016

 

 

 

290,786

 

EBITDA

$

(6,007,916

)

$

(3,751,569

)

$

(10,681,745

)

$

(5,894,648

)

The following table reconciles our net cash used in operating activities (the most directly comparable GAAP measure to Free Cash Flow) to Free cash flow for the three months ended June 30, 2023.

Three Months Ended

June 30,

 

2023

 

2022

Net cash used in operating activities

$

(4,649,235

)

$

(2,827,053

)

Capital expenditures

 

 

(481,071

)

 

 

(83,091

)

Free cash flow

$

(5,130,306

)

$

(2,910,144

)

The following table reconciles our net cash used in operating activities (the most directly comparable GAAP measure to Free Cash Flow) to Free cash flow for the six months ended June 30, 2023.

Six Months Ended

June 30,

 

2023

 

2022

Net cash used in operating activities

$

(8,699,808

)

$

(4,730,270

)

Capital expenditures

 

 

(825,872

)

 

 

(185,472

)

Free cash flow

$

(9,525,680

)

$

(4,915,742

)

Source: NUBURU, Inc.

Investor Relations:

Cody Slach & Ralf Esper

Gateway Group, Inc.

[email protected]

(949) 574-3860

Media Relations:

Zach Kadletz & Anna Rutter

Gateway Group, Inc.

[email protected]

(949) 574-3860

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Other Manufacturing Technology Other Technology Automotive Manufacturing Aerospace Manufacturing Batteries Machine Tools, Metalworking & Metallurgy Hardware

MEDIA:

Build-A-Bear Workshop to Announce Second Quarter Fiscal Year 2023 Results and Host Investor Conference Call on August 24, 2023

Build-A-Bear Workshop to Announce Second Quarter Fiscal Year 2023 Results and Host Investor Conference Call on August 24, 2023

ST. LOUIS–(BUSINESS WIRE)–
Build-A-Bear Workshop, Inc. (NYSE: BBW) today announced that the Company will report second quarter fiscal year 2023 results for the period ended July 29, 2023, on Thursday, August 24, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host its quarterly investor conference call to discuss the results at 9 a.m. ET on the same day.

The dial-in number for the live conference call is (201) 493-6780 (toll/international) or (877) 407-3982 (toll free). The access code is Build-A-Bear. The live Internet broadcast may be accessed at the Company’s investor relations website, http://IR.buildabear.com. The call is expected to conclude by 10 a.m. ET.

A replay of the conference call will be available via the internet and telephone. The replay of the conference call webcast will be available at the investor relations website for one year. A telephone replay will be available beginning at approximately 12 p.m. ET on Thursday, August 24, 2023, until 11:59 p.m. ET on August 31, 2023. The telephone replay is available by calling (412) 317-6671 (toll/international) or (844) 512-2921 (toll free). The access code is 13739859.

About Build-A-Bear

Build-A-Bear is a multi-generational global brand focused on its mission to “add a little more heart to life” appealing to a wide array of consumer groups who enjoy the personal expression in making their own “furry friends” to celebrate and commemorate life moments. Nearly 500 interactive brick-and-mortar retail locations operated through a variety of formats provide guests of all ages a hands-on entertaining experience, which often fosters a lasting and emotional brand connection. The company also offers engaging e-commerce/digital purchasing experiences on www.buildabear.com including its online “Bear-Builder” as well as the new “Bear Builder 3D Workshop”. In addition, extending its brand power beyond retail, Build-A-Bear Entertainment, a subsidiary of Build-A-Bear Workshop, Inc., is dedicated to creating engaging content for kids and adults that fulfills the company’s mission, while the company also offers products at wholesale and in non-plush consumer categories via licensing agreements with leading manufacturers. Build-A-Bear Workshop, Inc. (NYSE: BBW) posted total revenue of $467.9 million in fiscal 2022. For more information, visit the Investor Relations section of buildabear.com.

Investor Relations

Gary Schnierow, Vice President Investor Relations & Corporate Finance

[email protected]

Media Relations

[email protected]

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Retail Specialty Toys

MEDIA:

Amprius Technologies Reports Second Quarter 2023 Business and Financial Results

Amprius Technologies Reports Second Quarter 2023 Business and Financial Results

FREMONT, Calif.–(BUSINESS WIRE)–Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced its business and financial results for the second quarter of 2023, which ended June 30, 2023.

Amprius posted a letter to shareholders on its Investor Relations website, ir.amprius.com, that details the company’s second quarter results and provides an update on its business initiatives including product roadmap milestones, manufacturing scale-up progress, and customer acquisition efforts.

Management will also hold a live conference call and webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results and business updates.

Time: 5:00 p.m. ET (2:00 p.m. PT)

Toll-Free Number: 866-424-3442

International Number: 201-689-8548

Webcast:Register and Join

The conference call will be broadcast simultaneously and available for webcast replay here.

About Amprius Technologies, Inc.

Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries producing the industry’s highest known energy density cells. The company’s commercially available batteries deliver up to 450 Wh/kg and 1,150 Wh/L. The Company’s corporate headquarters is in Fremont, California where it maintains an R&D lab and a pilot manufacturing facility for the fabrication of silicon anodes and cells. To serve customer demand, Amprius recently entered into a lease agreement for an approximately 774,000-square-foot facility in Brighton, Colorado. For additional information, please visit amprius.com. Also, see the company’s LinkedIn and Twitter pages.

Investors

Tom Colton, Chris Adusei-Poku

Gateway Group, Inc.

949-574-3860

[email protected]

Media

Zach Kadletz, Brenlyn Motlagh

Gateway Group, Inc.

949-574-3860

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Batteries

MEDIA:

Logo
Logo

Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results

Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results

HAYWARD, Calif.–(BUSINESS WIRE)–
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023.

Business Updates

  • Demonstrated that an nsPFA cardiac clamp can consistently perform transmural ablations in cardiac muscle up to approximately 25 millimeters thick in 1.25 seconds in preclinical studies.

  • Demonstrated that an nsPFA cardiac ablation catheter can consistently perform circumferential ablations of targeted pulmonary veins in a single shot in approximately 5 seconds in preclinical studies.

  • Three abstracts highlighting the results of preclinical studies using an nsPFA cardiac ablation catheter device were presented by physician collaborators at the Annual Heart Rhythm Society Meeting.

  • Achieved positive patient tolerance, safety and tissue response in a first-in-human feasibility study of nsPFA delivery for the ablation of benign thyroid nodules.

  • Entered into a $65 million private placement stock purchase agreement with Robert Duggan, the Company’s Executive Chairman, effectively canceling all indebtedness owed by the Company to Mr. Duggan.

  • Further strengthened the balance sheet with gross proceeds of $14.6 million in the second quarter through the exercise of warrants from the Company’s June 2022 Rights Offering.

“We are encouraged by the preclinical results we have achieved with the nsPFA cardiac clamp and catheter products. Our novel devices, combined with our unique mechanism of action, are demonstrating the potential to advance the standard of care for the treatment of atrial fibrillation. Additionally, we view the preliminary findings in our first-in-human feasibility study using our proprietary nsPFA surgical end-effector to ablate benign thyroid nodules as a significant validation of our engineering and the potential for nsPFA to deliver safe and effective human tissue ablation in surgery,” said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. “Looking ahead, we remain focused on gaining clearance for a cardiac ablation clamp and advancing the catheter toward first-in-human studies.”

Second Quarter 2023 Results

Total GAAP cost and expenses, representing cost of revenues, research and development, sales and marketing, and general and administrative expenses, for the three months ended June 30, 2023, were $10.2 million compared to $14.3 million for the prior year period. Non-GAAP cost and expenses for the three months ended June 30, 2023, were $8.8 million compared to $12.2 million for the prior year period. The decrease in operating expenses compared to the prior year period was driven by the prior headcount reduction and restructuring.

GAAP net loss for the three months ended June 30, 2023 was ($9.9) million compared to ($14.0) million for the three months ended June 30, 2022. Non-GAAP net loss for the three months ended June 30, 2023, was ($8.5) million compared to ($11.9) million for the three months ended June 30, 2022.

Cash and cash equivalents totaled $58.7 million as of June 30, 2023, compared to $14.8 million as of June 30, 2022 and $54.1 million as of March 31, 2023. Cash used in the second quarter of 2023 was $10.0 million compared to $12.8 million in the same period in the prior year and $7.2 million used in the first quarter of 2023. The increase of second quarter cash usage was primarily due to the timing of certain nonrecurring payments. In the second quarter of 2023, the Company received $14.6 million in gross proceeds from the exercise of warrants issued in its June 2022 rights offering.

Reconciliations of GAAP to non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call today, August 10, 2023, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization and restructuring charges. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:

Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP cost and expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of time-based and performance-based options, such as options that vest as a result of the Company’s market capitalization. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.

Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP cost and expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.

Restructuring charges. The Company has excluded restructuring charges in calculating its non-GAAP cost and expenses and net loss measures. Restructuring programs involve discrete initiatives designed to improve operating efficiencies and include employee termination, contract termination, and other exit costs associated with the restructuring program. The Company believes that excluding discrete restructuring charges allows for better comparisons from period to period.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its cardiac clamp through the appropriate FDA regulatory path and possible initiation of a first-in-human safety feasibility study of its nsPFA cardiac ablation catheter system, statements concerning the Company’s future regulatory strategies and possible government clearances and approvals, statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation and benign thyroid nodules, statements about the Company’s future financing opportunities and operating expenses, and Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s nsPFA technology will become a disruptive treatment option for treating cardiac arrhythmias, benign thyroid nodules or any other medical condition and whether future clinical studies will show the CellFX System is safe and effective to treat atrial fibrillation, benign thyroid nodules or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

PULSE BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

June 30,

 

December 31,

 

2023

 

2022

ASSETS

Current assets:

Cash and cash equivalents

$

58,747

 

$

61,139

 

Prepaid expenses and other current assets

1,211

 

1,008

 

Total current assets

 

59,958

 

 

62,147

 

 

Property and equipment, net

1,755

 

1,961

 

Intangible assets, net

2,218

 

2,551

 

Goodwill

2,791

 

2,791

 

Right-of-use assets

7,670

 

8,062

 

Other assets

365

 

365

 

Total assets

$

74,757

 

$

77,877

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

1,794

 

$

1,573

 

Accrued expenses

2,844

 

2,595

 

Lease liability, current

975

 

896

 

Related party note payable, current

 

917

 

Total current liabilities

 

5,613

 

 

5,981

 

 

Lease liability, less current

8,644

 

9,144

 

Related party note payable, less current

 

 

 

65,000

 

Total liabilities

 

14,257

 

 

80,125

 

 

Stockholders’ equity:

Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding

 

 

Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 54,771 shares and 37,235 shares at June 30, 2023 and December 31, 2022, respectively

55

 

37

 

Additional paid-in capital

374,861

 

292,420

 

Accumulated other comprehensive income (loss)

 

 

Accumulated deficit

(314,416

)

(294,705

)

Total stockholders’ (deficit) equity

 

60,500

 

 

(2,248

)

Total liabilities and stockholders’ equity

$

74,757

 

$

77,877

 

PULSE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three-Month Periods Ended

 

Six-Month Periods Ended

 

 

June 30,

 

June 30,

 

 

2023*

 

2022

 

2023*

 

2022

Revenues:

Product revenues

$

 

$

265

 

$

 

$

709

 

Total revenues

 

 

265

 

 

 

 

709

 

Cost and expenses:

Cost of revenues

 

1,344

 

 

2,253

 

Research and development

6,697

 

5,458

 

12,526

 

12,227

 

Sales and marketing

 

3,690

 

 

9,231

 

General and administrative

3,530

 

3,787

 

7,263

 

8,285

 

Total cost and expenses

 

10,227

 

 

14,279

 

 

19,789

 

 

31,996

 

Loss from operations

(10,227

)

(14,014

)

(19,789

)

(31,287

)

Other income:

Interest income, net

 

317

 

 

18

 

 

78

 

 

18

 

Total other income

317

 

18

 

78

 

18

 

Net loss

 

(9,910

)

 

(13,996

)

 

(19,711

)

 

(31,269

)

Other comprehensive gain:

Unrealized gain on available-for-sale securities

 

 

 

 

Comprehensive loss

$

(9,910

)

$

(13,996

)

$

(19,711

)

$

(31,269

)

Net loss per share:

Basic and diluted net loss per share

$

(0.22

)

$

(0.44

)

$

(0.48

)

$

(1.02

)

Weighted average shares used to compute net loss per common share — basic and diluted

 

44,512

 

 

31,492

 

 

40,970

 

 

30,623

 

 
 

Three-Month Periods Ended

 

Six-Month Periods Ended

June 30,

 

June 30,

Stock Based Compensation Expense:

2023*

 

2022

 

2023*

 

2022

Cost of revenues

$

$

90

$

$

180

Research and development

518

496

776

953

Sales and marketing

362

816

General and administrative

625

765

1,263

1,771

Total stock-based compensation expense

$

1,143

$

1,713

$

2,039

$

3,720

 

*For the three- and six-month periods ended June 30, 2023, the Company reclassified certain expenses as a result of the shift in focus from dermatology to cardiology. Expenses previously included in Cost of Revenues are now recorded as a part of Research and Development, and expenses previously included in Sales and Marketing are now recorded as a part of General and Administrative.

PULSE BIOSCIENCES, INC.

Consolidated Revenue Financial Highlights

(In thousands)

(Unaudited)

 

Three-Month Periods Ended

Six-Month Periods Ended

June 30,

June 30,

2023

 

2022

2023

 

2022

Revenue by category:

Systems

$

0

%

$

209

79

%

$

0

%

$

576

81

%

Cycle units

0

%

56

21

%

0

%

133

19

%

Total revenue

$

0

%

$

265

100

%

$

0

%

$

709

100

%

 

Revenue by geography:

North America

$

0

%

$

214

81

%

$

0

%

$

526

74

%

Rest of World

0

%

51

19

%

0

%

183

26

%

Total revenue

$

0

%

$

265

100

%

$

0

%

$

709

100

%

Reconciliation of GAAP to Non-GAAP Financial Measures

The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three-Month Periods Ended

 

Six-Month Periods Ended

 

June 30,

 

June 30,

 

2023

 

2022

 

2023

 

2022

Reconciliation of GAAP to non-GAAP Cost of revenues:

GAAP Cost of revenues

$

 

$

1,344

 

$

 

$

2,253

 

Less: Stock-based compensation expense

 

(90

)

 

(180

)

Less: Depreciation and amortization

 

(5

)

 

(10

)

Less: Restructuring

 

 

 

(19

)

Non-GAAP Cost of revenues

$

 

$

1,249

 

$

 

$

2,044

 

 

Reconciliation of GAAP to non-GAAP Research and development:

GAAP Research and development

$

6,697

 

$

5,458

 

$

12,526

 

$

12,227

 

Less: Stock-based compensation expense

(518

)

(496

)

(776

)

(953

)

Less: Depreciation and amortization

(59

)

(70

)

(117

)

(129

)

Less: Restructuring

 

 

(38

)

(127

)

Non-GAAP Research and development

$

6,120

 

$

4,892

 

$

11,595

 

$

11,018

 

 

Reconciliation of GAAP to non-GAAP Sales and marketing:

GAAP Sales and marketing

$

 

$

3,690

 

$

 

$

9,231

 

Less: Stock-based compensation expense

 

(362

)

 

(816

)

Less: Depreciation and amortization

 

(15

)

 

(28

)

Less: Restructuring

 

 

 

(546

)

Non-GAAP Sales and marketing

$

 

$

3,313

 

$

 

$

7,841

 

 

Reconciliation of GAAP to non-GAAP General and administrative:

GAAP General and administrative

$

3,530

 

$

3,787

 

$

7,263

 

$

8,285

 

Less: Stock-based compensation expense

(625

)

(765

)

(1,263

)

(1,771

)

Less: Depreciation and amortization

(244

)

(263

)

(488

)

(513

)

Less: Restructuring

(7

)

 

(19

)

(41

)

Non-GAAP General and administrative

$

2,654

 

$

2,759

 

$

5,493

 

$

5,960

 

 

Reconciliation of GAAP to non-GAAP Cost and expenses:

GAAP Cost and expenses

$

10,227

 

$

14,279

 

$

19,789

 

$

31,996

 

Less: Stock-based compensation expense

(1,143

)

(1,713

)

(2,039

)

(3,720

)

Less: Depreciation and amortization

(303

)

(353

)

(605

)

(680

)

Less: Restructuring

(7

)

 

(57

)

(733

)

Non-GAAP Cost and expenses

$

8,774

 

$

12,213

 

$

17,088

 

$

26,863

 

 

Reconciliation of GAAP to non-GAAP Net loss:

GAAP Net loss

$

(9,910

)

$

(13,996

)

$

(19,711

)

$

(31,269

)

Add: Stock-based compensation expense

1,143

 

1,713

 

2,039

 

3,720

 

Add: Depreciation and amortization

303

 

353

 

605

 

680

 

Add: Restructuring

7

 

 

57

 

733

 

Non-GAAP Net loss

$

(8,457

)

$

(11,930

)

$

(17,010

)

$

(26,136

)

 

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

[email protected]

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Health Technology Health Medical Devices

MEDIA:

Logo
Logo

Savara Reports Second Quarter Financial Results and Provides Business Update

Savara Reports Second Quarter Financial Results and Provides Business Update

  • Fully Enrolled Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Report Top Line Data by End of 2Q 2024

    48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease
  • ~$105M in Cash and Cash Equivalents at the End of 2Q 2023
  • Further Strengthened Balance Sheet in July with an ~$80M Equity Financing, Resulting in ~$180M in Pro Forma Cash After Giving Effect to the Offering
  • Anne Erickson, SVP, Global Business Operations, Promoted to Chief Business Officer, Effective Immediately

LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2023 and provided a business update.

“The Company continues to make strong progress with the molgramostim development program,” said Matt Pauls, Chair and CEO, Savara. “In June, we announced the Phase 3 IMPALA-2 trial completed enrollment on-time with 164 patients randomized, four more than the target of 160, and our timeline remains on track for top line results by the end of 2Q 2024. Additionally, last month we further strengthened our balance sheet through an $80 million equity raise and now have approximately $180 million in pro forma cash.”

Second Quarter Financial Results (Unaudited)

Savara’s net loss for the second quarter of 2023 was $11.4 million, or $(0.07) per share, compared with a net loss of $9.2 million, or $(0.06) per share, for the second quarter of 2022.

Research and development expenses increased by $2.5 million, or 38.8%, to $8.9 million for the three months ended June 30, 2023 from $6.4 million for the three months ended June 30, 2022. This increase is primarily due to the performance of tasks related to our molgramostim program which includes increases of ~$0.6 million of costs related to our chemistry, manufacturing, and controls activities, ~$1.4 million of costs related to our IMPALA-2 trial, including contract research organization related activities, and ~$0.5 million in personnel and related costs.

General and administrative expenses increased by $0.3 million, or 11.7%, to $3.3 million for the three months ended June 30, 2023 from $3.0 million for the three months ended June 30, 2022. The increase is due to the hiring of additional personnel for key positions in the first quarter and related costs to facilitate the management of our business and operations.

As of June 30, 2023, the Company had cash, cash equivalents and short-term investments of ~$105.2 million and debt of ~$26.2 million.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements related to the timing of reporting of top line data. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks and uncertainties relating to the impact of widespread health concerns impacting healthcare providers or patients, disruptions or inefficiencies in the supply chain and geopolitical conditions on our business and operations, the outcome of our ongoing and planned clinical trials for our product candidate, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as molgramostim that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Financial Information to Follow

Savara Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except for share and per share amounts)
Unaudited
 

Three months ended

 

Six months ended

June 30,

 

June 30,

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 
Operating expenses:
Research and development

$

8,911

 

$

6,418

 

$

17,649

 

$

12,102

 

General and administrative

 

3,302

 

 

2,957

 

 

6,668

 

 

5,311

 

Depreciation and amortization

 

8

 

 

8

 

 

16

 

 

16

 

Total operating expenses

 

12,221

 

 

9,383

 

 

24,333

 

 

17,429

 

 
Loss from operations

 

(12,221

)

 

(9,383

)

 

(24,333

)

 

(17,429

)

 
Other income (expense), net:

 

778

 

 

219

 

 

2,333

 

 

(35

)

 
Net loss attributable to common stockholders

$

(11,443

)

$

(9,164

)

$

(22,000

)

$

(17,464

)

 
Net loss per share – basic and diluted

$

(0.07

)

$

(0.06

)

$

(0.14

)

$

(0.11

)

 
Weighted average shares – basic and diluted

 

152,796,617

 

 

152,771,103

 

 

152,778,031

 

 

152,770,434

 

 
Other comprehensive loss

 

(158

)

 

(725

)

 

(14

)

 

(1,021

)

 
Total comprehensive loss

$

(11,601

)

$

(9,889

)

$

(22,014

)

$

(18,485

)

Savara Inc. and Subsidiaries
Condensed Consolidated Balance Sheet Data
(in thousands)
(Unaudited)
 

June 30,

 

December 31,

 

2023

 

 

2022

Cash, cash equivalents, and short-term investments

$

105,179

$

125,876

 
Working capital

 

102,015

 

123,087

 
Total assets

 

119,833

 

139,777

 
Total liabilities

 

32,118

 

31,999

 
Stockholders’ equity:

 

87,715

 

107,778

 

Savara Inc. IR & PR

Anne Erickson ([email protected])

(512) 851-1366

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo

Dun & Bradstreet Recognized With 2023 Tech Cares Award for Strong Commitment to Corporate Social Responsibility

Dun & Bradstreet Recognized With 2023 Tech Cares Award for Strong Commitment to Corporate Social Responsibility

JACKSONVILLE, Fla.–(BUSINESS WIRE)–
Dun & Bradstreet (NYSE:DNB), a leading global provider of business decisioning data and analytics, has been awarded a 2023 Tech Cares Award from TrustRadius, a B2B technology decisioning platform, for the company’s dedicated commitment and impactful Corporate Social Responsibility (CSR) programs for employees and surrounding communities.

The 2023 Tech Cares Awards recognize companies who have demonstrated exceptional corporate social responsibility, with particular focus on volunteerism, Diversity, Equity, and Inclusion (DEI) programs, charitable donations and fundraising, workplace culture, and demonstrable support for environmental sustainability.

“We are grateful for the recognition of the work that our company has been doing, and continues to do, to give back to the communities we serve and to create a culture where our team members can be their best selves,” said Michele Caselnova, Chief Sustainability & Communications Officer, Dun & Bradstreet. “We are honored to be recognized by TrustRadius and are ever mindful of our responsibility to make a positive and sustainable impact in all that we do.”

Dun & Bradstreet’s global giving and volunteering program, called “Do Good,” engages employees and further enables their potential to have a positive impact in their local communities. Employees receive 16 hours of paid volunteer time off annually to volunteer independently in their communities or alongside their colleagues during local volunteer events organized by Dun & Bradstreet. In 2022, Dun & Bradstreet employees invested 8,702 hours of their time to their communities through the “Do Good” program.

The company is committed to creating a collaborative workplace with a focus on DEI programs, including Employee Resource Groups (ERGs). Dun & Bradstreet’s ERGs are designed to bring team members with commonalities together to collectively exchange ideas, experiences, and challenges in a safe and stigma-free setting. Each ERG’s activities are aligned with company goals and objectives, in addition to initiatives unique to the respective interests and passions of its members. This universal alignment ensures ERG activities remain beneficial to employees’ personal and career development, as well as the strategic growth of Dun & Bradstreet.

Dun & Bradstreet’s Environmental, Social and Governance (ESG) program includes three key pillars: reducing the impact the company’s operations have on the environment; fostering diversity and inclusivity by providing opportunities for Dun & Bradstreet employees and local communities to thrive; and demonstrating the company’s commitment to integrity by creating policies, practices, and solutions that reduce risk and create a positive impact. For more information, please visit dnb.com/esg.

About Dun & Bradstreet

Dun & Bradstreet, a leading global provider of business decisioning data and analytics, enables companies around the world to improve their business performance. Dun & Bradstreet’s Data Cloud fuels solutions and delivers insights that empower customers to accelerate revenue, lower cost, mitigate risk, and transform their businesses. Since 1841, companies of every size have relied on Dun & Bradstreet to help them manage risk and reveal opportunity. For more information on Dun & Bradstreet, please visit www.dnb.com.

Media Contact:

Dawn McAbee

904-648-6328

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Environment Consulting Professional Services Sustainability Philanthropy DEI (Diversity, Equity and Inclusion) Fund Raising Data Analytics Environmental, Social and Governance (ESG) Other Philanthropy

MEDIA:

Logo
Logo